Castle Biosciences’ Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the Houston Business Journal

Core Insights - Castle Biosciences' CEO Derek Maetzold has been recognized as a 2025 Most Admired CEO by the Houston Business Journal for his exceptional leadership and contributions to the community [3][4] - The award highlights the importance of financial stewardship and fostering inclusive workplace cultures, which are key aspects of Maetzold's leadership approach [3][4] Company Overview - Castle Biosciences (Nasdaq: CSTL) is a diagnostics company focused on improving health through innovative tests that guide patient care [5] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [5] Product Portfolio - Castle's current portfolio includes diagnostic tests for skin cancers, Barrett's esophagus, and uveal melanoma [6] - The company is also engaged in research and development for additional tests addressing high clinical needs, including a test for guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis [6]